VALIDITY OF SELF REPORTED FAMILY HISTORY OF LYMPHOMAS

自我报告的淋巴瘤家族史的有效性

• 批准号: 6197354
• 负责人: SALLY L GLASER
• 金额: $ 6.71万
• 依托单位: CANCER PREVENTION INSTIT OF CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-01 至 2002-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6197354
• 关键词: Hodgkin's disease; cancer risk; case history; clinical research; family genetics; female; human subject; lymphoma; neoplasm /cancer epidemiology; neoplasm /cancer genetics; women's health

Hodgkin's disease (HD) risk is increased in family members of patients. If proband-reported family histories of HD were known to be accurate, efficient studies of HD family association, inheritance patterns and susceptibility genes could be conducted without additional patient contact, using new statistical methods and stored tumor tissues. However, no data exist on the validity of self-reported family history of HD or other lymphoma, with which HD is often confused. In a prior population-based, case- control study of HD for which we interviewed 645 women and enumerated their 1st-, 2nd-, and 3rd-degree blood relatives, we found a significant excess of familial HD, the first such population-based finding. The proposed R03 study will validate the positive family histories of HD and other lymphoma provided by 50 probands, against medical record and/or death certificate reports, to explore the utility of proband-reported family histories for future genetic studies of familial HD, and to provide the first population-based description of validated familial HD and associated risk in women. The study will: 1) interview the 33 HD case and 17 population-control probands by phone for contact information on the 58 blood relatives they had reported as having HD or other lymphoma; 2) contact the 58 relatives or their next-of-kin by phone to obtain their cancer history and access to pathology reports and discharge summaries, or, as needed, death certificates, for diagnostic review; 3) obtain the diagnostic documents, and review and classify diagnoses per cancer-registry standards; 4) compare reported and documented diagnoses to calculate validity of proband-reported family history of HD and of other lymphoma, for 1st-, 2nd-, and selected 3rd-degree relatives; 5) describe validated familial HD and associated risk in the original population-based HD case series. Study strengths are: 1) inclusion of population-based, proband-derived histories for 1st-, 2nd-, and selected 3rd- relatives, so that findings are both generalizable and extend beyond 1st-degree relatives; 2) validation of HD and of other lymphomas, both reported in high-risk families but often hard to differentiate; 3) use of a documentation hierarchy: medical record, death certificate, and relative's self-report. Establishing validity of proband-reported lymphomas will help us determine the usefulness of high-risk pedigrees reported by HD probands, who could be identified for this purpose efficiently and in adequate numbers by cancer-registry screening, and will expand the literature on cancer-history validation to include HD. Study results also have implications to the utility of self- reported family history of lymphoma for counseling lymphoma family members about disease risk.

霍奇金氏病（HD）的风险增加了患者的家庭成员。 如果已知HD的概率报告家庭历史是对HD家族关联的准确，有效的研究，则可以使用新的统计方法和存储的肿瘤组织进行遗传模式和易感基因。 但是，没有关于高清或其他淋巴瘤的自我报告家族史的有效性的数据，而HD通常会混淆。 在先前基于人群的HD病例控制研究中，我们采访了645名妇女，并列举了其第一，第二和第三级血液亲戚，我们发现家族性高清大量过量，这是第一个基于人群的发现。 拟议的R03研究将验证50个概率和/或死亡证书报告提供的HD和其他淋巴瘤的积极家庭历史，以探讨有关家族性HD的未来遗传研究的实用性，并为妇女提供了基于人群的家族HD和相关风险的首次基于人群的遗传研究。 该研究将：1）通过电话采访33个高清病例和17个人口控制概率，以获取有关其报告为HD或其他淋巴瘤的58个血液亲戚的联系信息； 2）通过电话与58个亲戚或近亲联系，以获取其癌症病史，并获得病理报告和出院摘要，或者根据需要的死亡证书进行诊断审查； 3）获取诊断文件，并根据癌症注册标准审查和分类诊断； 4）比较并记录了记录的诊断，以计算HD和其他淋巴瘤的家族史的有效性，并为第一个，第二次，第三级亲戚进行比较； 5）描述原始基于人群的HD病例系列中经过验证的家族性高清和相关风险。 研究优势是：1）包括1st，第二和选定的第三亲戚的基于人群的，基于概率和衍生的历史，因此发现既可以推广，又超过一级亲戚； 2）对高清和其他淋巴瘤的验证，都在高危家族中报告，但通常很难区分； 3）使用文档层次结构：病历，死亡证明和亲戚的自我报告。建立探针和报告的淋巴瘤的有效性将有助于我们确定HD Probands报告的高风险血统的有用性，HD Probands可以通过癌症注册筛查有效地识别出为此目的而确定的，并将扩大有关癌症历史验证的文献，包括HD。研究结果也对自我报道的淋巴瘤家族史的效用也有影响，以咨询淋巴瘤家庭成员有关疾病风险。